Alkermes vs ANI Pharmaceuticals
Alkermes reported revenue of $1.5 billion in fiscal 2025, 1.7 times ANI Pharmaceuticals' $883 million in fiscal 2025. Alkermes' revenue fell 5.2% in its latest year, and ANI Pharmaceuticals' grew 43.8%. Alkermes had an operating margin of 17.2%, against 12.6% at ANI Pharmaceuticals. Free cash flow was $480 million at Alkermes and $171 million at ANI Pharmaceuticals.
Side by side
| Alkermes | ANI Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.5B | $883M |
| Revenue growth | −5.2% | 43.8% |
| Revenue growth a year, last 5 years | 7.3% | 33.5% |
| Gross margin | 86.7% | — |
| Operating margin | 17.2% | 12.6% |
| Net margin | 16.4% | 8.9% |
| Free cash flow | $480M | $171M |
| Free cash flow margin | 32.5% | 19.4% |
| Return on capital | — | 15.9% |
| Net debt to EBITDA | — | 0.1x |
| Dividends and buybacks | $0M | $13M |
| Change in diluted share count | −0.3% | 9.9% |
| Last close | $44.44 | $72.60 |
| P/E at the last close | 116.9× | 15.7× |
| Insider trades, last 12 months | sold $10.2 million | sold $15.0 million |
| Piotroski F-score | — | 6 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AlkermesANI Pharmaceuticals
Operating margin
Percent of revenue
AlkermesANI Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AlkermesANI Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alkermes and ANI Pharmaceuticals pages.